Rituximab and ABVD for Hodgkin's Patients

Completed · Phase 2

Conditions studied: Lymphoma

In brief

Primary Objective: \- To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.

Key facts

Study ID

NCT00504504

Run by

M.D. Anderson Cancer Center

People needed

85

Starts

2001-03-01

Expected to finish

2012-03-01

Last updated by the study team

2013-07-09

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hodgkin's disease patients who relapse after radiation therapy alone and previously untreated patients with stage II bulky, III and IV who are eligible for ABVD.
• Must have histologically proven diagnosis of Hodgkin's disease (Nodular sclerosis or mixed cellularity).
• Must have bidimensionally measurable disease.
• Must sign a consent form.
• Must be older than 16 years of age.
• Must have adequate bone marrow reserve (ANC > 1,000/microL, Platelet > 100,000/microL
• Left Ventricular Ejection Fraction (LVEF) >/= 50% by multigated acquisition (MUGA) scan or echocardiogram.
• Serum creatinine < 2 mg/dl, serum bilirubin < 2 mg/dl

You may not qualify if…

• HIV positive.
• Pregnant women and women of child bearing age who are not practicing adequate contraception.
• Prior chemotherapy.
• Severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and asthma.

Where it is running

• UT MD . Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.